Exact Launches Real-World Trial Of Cologuard Colon Cancer Screening
Executive Summary
Exact Sciences Corp. and the Mayo Clinic are launching a 150,000-patient clinical trial examining the real-world effects of colorectal cancer screening with the Cologuard colon cancer test.
You may also be interested in...
USPSTF Recommendations For Colon Cancer Screening At Age 45 Could Give Cologuard A Boost
If the USPSTF recommendations are finalized, most insurers would need to reimburse Exact Sciences’ US FDA-approved at-home stool DNA test for colorectal cancer and encourage doctors to prescribe more at-home testing.
Despite Only Two Parallel Review Success Stories, CMS Touts Better Coordination
While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.